IRIX - Earnings announcements

MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights Generated total revenue of $11.8 million, compared to $11.9 million in the prior year periodCyclo G6® product family revenue was $3.6 million, representing growth of 14% year-over-year compared to $3.2 million in the prior year period Sold 15,500 Cyclo G6 probes compared to 13,900 in the prior year periodSold 24 Cy

MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 93

MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl

MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro

MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior year quarterCyclo G6® product family revenue was $3.5 million, representing growth of 13% year-over-year compared to $3.1 million in the prior year quarter Sold 14,900 Cyclo G6 probes comp

MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 from the US or +1-646-968-2525 internationally and providi

MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights Generated total revenue of $13.6 million, representing growth of 7% year-over-year and 14% sequential growth versus the first quarter of 2025Cyclo G6® product family revenue was $3.3 million, essentially flat year-over-year Sold 13,100 Cyclo G6 probes compared to 15,100 in the prior year quarterSold 35 Cyclo G6

MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing passcode: 2197032 followed by pre

MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. The Company's management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live an

MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 Results & Recent Highlights Achieved positive adjusted EBITDA in the fourth quarter of 2024Successfully implemented previously announced cost reduction program, resulting in operating expenses of $6.1 million, a 24% reduction compared to $8.0 million in the prior year periodGenerated total revenue of $12.7 mil

MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the "Transaction"). The sole counterparty to the Transaction is Novel Inspiration International Co., Ltd. ("Novel"), an investment company founded in 2020, which had the assistance of William Moore, formerly both a board m

MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility. The company is not aware of any material developments or changes to its operating or financial condition that precipitated the volume and price movements that occurred on March 13, 2025. There have been no material adverse changes to the company's operating results, its business, strategy, or prospects since the company provided preliminary operating and financial results for the fourth quarte

MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and re

MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Financial and Recent Highlights Expects to achieve EBITDA breakeven in the fourth quarter of 2024 as a result of actions to reduce costs and improve profitabilityGenerated total revenue of $11.6 million, representing a decline of 8% sequentially from the second quarter of 2024 and a decline of 10% over Q3'23Cyclo G6® product fami

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for interna

MOUNTAIN VIEW, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 29, 2024, and provided a business update. Second Quarter 2024 Financial and Recent Highlights Generated total revenue of $12.6 million, representing sequential growth of 7% from the first quarter of 2024Cyclo G6® product family revenue was $3.3 million, representing sequential growth of 13% from the first quarter of 2024 Sold 15,100 Cyclo G6 probes, compared to

MOUNTAIN VIEW, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter 2024 and provide a business update after the close of trading on Thursday, August 8, 2024. The Company's management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (646) 307-1963 for domestic callers or (800) 715-9871 for international cal

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update. First Quarter 2024 Financial Highlights Generated total revenue of $11.8 million, compared to $13.7 million in the prior year periodCyclo G6® product family revenue in the first quarter of $3.0 million, compared to $3.7 million in the prior year period Sold 13,300 Cyclo G6 probes, compared to 12,700 in the prior quarter a

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Generated total revenue of $12.5 million, compared to $15.2 million in the prior year periodCyclo G6® product family revenue in the fourth quarter of $3.0 million, compared to $4.2 million in the prior year period Sold 12,700 Cyclo G6 probes, co

MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the

MOUNTAIN VIEW, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced all five Medicare Administrative Contractors ("MACs") retired their local coverage determinations ("LCDs") that were scheduled to take effect on January 29, 2024.   Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate for continued patient access to clinically proven safe and effective glaucoma treatments. The Company applauds the decision which effec

MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. Recent Business Updates Generated total revenue of $12.9 million, representing flat sequential quarter revenue and a decrease of 12% year-over-yearCyclo G6® product family revenue in the third quarter of $3.0 million, representing a decrease 12% year-over-year due to reduced systems sales Sold 13,200 Cyclo G6 probes,

MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY. Third Quarter Earnings Conference CallThe Company's management team will host a conference to discuss reported financial results and business updates beginning at 2:00 p.m. PT / 5:00 p.m. ET on November 14, 2023. Stifel 2023 Healthcare ConferenceManagement is sched

MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023. About IridexIridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effect

MOUNTAIN VIEW, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023. Second Quarter 2023 Highlights Generated total revenue of $12.9 million, a decrease of 7% year-over-yearCyclo G6® product family revenue of $3.7 million increased 5% year-over-year 41 Cyclo G6 Glaucoma Laser Systems sold, compared to 48 in the prior year period15,500 Cyclo G6 probes sold representing a 9% revenue increase and 4% unit increase year-over-year Retina product revenue was $6.9 million, a de

MOUNTAIN VIEW, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company's website at: www.iridex.com. About IridexIrid

MOUNTAIN VIEW, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023. First Quarter 2023 Highlights Generated total revenue of $13.7 million, an increase of 2% year-over-yearCyclo G6® product family revenue of $3.7 million increased 4% year-over-year 61 Cyclo G6 Glaucoma Laser Systems sold, compared to 56 in the prior year periodCyclo G6 probe revenue increased 6% year-over-year on decreased unit sales of 13,800 probes Retina product revenue of $7.2 million was essentially flat

MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023.   The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company's website at: www.iridex.com. About IridexIride

MOUNTAIN VIEW, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance. Fourth Quarter 2022 & Recent Highlights Generated total revenue of $15.2 million, essentially unchanged from the prior year periodCyclo G6® product family revenue of $4.2 million, an increase of 9% year-over-year 16,400 Cyclo G6 probes sold, a quarterly record and 8% increase year-over-year79 Cyclo G6 Glaucoma Laser Systems sold, compared to 90 in the prior y

MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year 2022 after the close of trading on Thursday, March 9, 2023. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company's website at: www.iridex.com. About I

MOUNTAIN VIEW, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights Total revenue of $14.6 million, a record third quarter revenue, and an increase of 10% over the prior year periodGross Margin was 44.1% compared to 43.6% in the prior year periodCyclo G6® product family revenue of $3.5 million, an increase of 10% year-over-year 13,680 Cyclo G6 probes sold, a 2% increase year-over-year54 Cyclo G6 Glaucoma Laser Systems sold, compared to 42

MOUNTAIN VIEW, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the "Event Calendar" page of the "Investors" section of the Company's website at: www.iridex.com. About IridexIri

MOUNTAIN VIEW, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX) today reported financial results for the second quarter ended July 2, 2022. Second Quarter 2022 Highlights Total revenue of $13.8 million, an increase of 2% over the prior year periodGross Margin was 45.6% compared to 45.5% in the prior year periodCyclo G6® product family revenue of $3.5 million, a decrease of 3% year-over-year 15,000 Cyclo G6 probes sold, a 6% decrease year-over-year and a 2% increase quarter-over-quarter48 Cyclo G6 Glaucoma Laser Systems sold, compared to 47 in the prior year quarter Retina product revenue was relatively flat year-over-year at $7.5 millionNet Cash use of $2.7 mil

MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2022 after the close of trading on Monday, August 15, 2022. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by registering here. Participants are required to register at a minimum 15 minutes before the start of the call. To listen to the live webcast and a replay, plea

MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX) today reported financial results for the first quarter ended April 2, 2022. First Quarter 2022 Highlights Record first quarter revenue of $13.4 million, an increase of 12% from the prior year periodCyclo G6® product family revenue of $3.5 million, an increase of 6% year-over-year 14,700 Cyclo G6 probes sold, an 8% increase year-over-year56 Cyclo G6 Glaucoma Laser Systems sold, compared to 64 in the prior year Retina product revenue increased 10% year-over-year to $7.3 million PASCAL® products acquired from Topcon contributed 29% of retina revenue Net Cash use of $3.2 million resulting in cas

MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 12, 2022. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 3366993. A live and archived webcast of the event w

MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX) today reported financial results for the fourth quarter and year ended January 1, 2022. Fourth Quarter Highlights Total revenue of $15.3 million, a new quarterly record, representing an increase of 24% from the prior year periodCyclo G6® product family revenue of $3.9 million, an increase of 11% year-over-year 15,200 Cyclo G6 probes sold, a 13% increase year-over-year90 Cyclo G6 Glaucoma Laser Systems sold, compared to 57 in the prior year Retina product revenue increased 31% year-over-year to $9.1 million Pascal® products acquired from Topcon contributed 17% of

MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, March 10, 2022. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1574126. A live and archived webcast

MOUNTAIN VIEW, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX) today reported financial results for the third quarter ended October 2, 2021. Third Quarter Highlights Revenue of $13.3 million, an increase of 51% from the prior year period, and 24% compared to third quarter 2019 Gross margin of 43.6%, an improvement over 41.5% in the same period last yearCash usage of $0.7 million leading to cash at quarter-end of $25.6 million Cyclo G6® product family revenue of $3.1 million, an increase of 13% year-over-year 13,400 Cyclo G6 probes sold, an 18% increase year-over-year42 Cyclo G6 Glaucoma Laser Systems sold, compared to 37 in the prior year period Retina product

MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 7496524. A live and archived webcast of the eve

Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe SalesIncreases Full Year 2021 Guidance MOUNTAIN VIEW, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX) today reported financial results for the second quarter ended July 3, 2021. Second Quarter Highlights Revenue of $13.4 million, highest since 2007, increased 116% from the prior year period, and 29% compared to second quarter 2019Gross profit of $6.1 million, also a 14-year quarterly high, on gross margin of 45.5%Cyclo G6® product family revenue of $3.6 million, an increase of 70% year-over-year Record 16,000 Cyclo G6 probes sold, a 103% year-over-year increase 47 Cyclo G6 Glaucoma

MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 12, 2021. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 9257308. A live and archived webcast of the even